Clostridium
Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
Published in Vaccine Weekly, March 4th, 2009
The trial currently conducted in the United Kingdom is investigating the safety and efficacy of sanofi pasteur's C. difficile candidate vaccine. While the target indication for the vaccine is primary prevention of C. difficile infection (CDI), this trial in infected patients aims at providing early proof of concept of the vaccine approach.
"Treatment of C....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-03-04)
More Articles from Vaccine Weekly
- Lifespan
Study calls for increased research in flu transmission to prepare for pandemic flu outbreak - Oregon Health & Science University
OHSU vaccine research targets HIV in the slower, early stage of infection - Adenovirus
Studies from V. Tsai et al add new findings in the area of adenovirus - Bacillus Calmette-Guerin Vaccines
Research results from Food & Drug Administration update knowledge of Bacillus calmette-guerin vaccines - DNA Vaccines
Research from B.J. Lu et al broadens understanding of DNA vaccines - DNA Vaccines
Scientists at Fourth Military Medical University target DNA vaccines - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
